Therapeutic antibodies to intracellular targets in cancer therapy

Expert Opinion on Biological Therapy

Volumn 13, Issue 11, 2013, Pages 1485-1488

  Veomett, Nicholas ^a   Dao, Tao ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody therapy; ESK1; HLA; Intracellular antigens; MHC class I presentation; TCR mimic; TCR like; Tumor necrosis therapy

Indexed keywords

ANTIBODY DRUG CONJUGATE; CELL PROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A ANTIGEN; HLA ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MONOCLONAL ANTIBODY; PROTEIN P68; RADIOIMMUNOCONJUGATE; RNA HELICASE; SINGLE STRANDED DNA; T CELL RECEPTOR MIMIC ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WT1 PROTEIN; ZINC FINGER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIBODY THERAPY; ANTIGEN PRESENTATION; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER THERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOLECULARLY TARGETED THERAPY; MOLECULE; MOUSE; NONHUMAN; ONCOGENE; PROSTATE CANCER; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; EPITOPES; HLA ANTIGENS; HUMANS; IMMUNOLOGIC SURVEILLANCE; INTRACELLULAR SPACE; MOLECULAR TARGETED THERAPY; NECROSIS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS;

EID: 84885630721     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.833602     Document Type: Review

References (15)

1. Khawli LA, Hu P, Epstein AL. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Handb Exp Pharmacol 2008(181):291-328
2. Noguchi T, Kato T, Wang L, et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res 2012á72(7):1672-82
3. Guo K, Li J, Tang JP, et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 2011á3(99):99ra85
4. Andersen PS, Stryhn A, Hansen BE, et al. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci USA 1996á93(5):1820-4
5. Dahan R, Reiter Y. T-cell-receptor-like antibodies - generation, function and applications. Expert Rev Mol Med 2012á14:e6
6. Dao T, Yan S, Veomett N, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013á5(176): 176ra33
7. Sugiyama H. WT1 (Wilms' tumor gene 1): Biology and cancer immunotherapy. Jpn J Clin Oncol 2010 40(5):377-87
8. Klechevsky E, Gallegos M, Denkberg G, et al. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res 2008á68(15):6360-7
9. Epel M, Carmi I, Soueid-Baumgarten S, et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol 2008á38(6):1706-20
10. Verma B, Jain R, Caseltine S, et al. TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. J Immunol 2011á186(5):3265-76
11. Sergeeva A, Alatrash G, He H, et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011á117(16):4262-72
12. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: An engineer's perspective. Drug Discov Today 2007á12(21-22):898-910
13. Kubota T, Niwa R, Satoh M, et al. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009á100(9):1566-72
14. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001á294(5546):1537-40
15. Doubrovina E, Carpenter T, Pankov D, et al. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood 2012á120(8):1633-46